Brought to you by 
Rare disease start-up Harmony raises $270mm in early equity funding
09 Oct 2017
Executive Summary
Concurrent with procuring an exclusive US license to Bioprojet's narcolepsy candidate pitolisant, Harmony Biosciences LLC (developing rare disease therapeutics) announced it raised $270mm in equity financing (assumed to be its Series A round) from 29 investors, including Valor Equity Partners, Fidelity Management & Research, HBM Healthcare Investments, Vivo Capital, venBio Partners, Novo Holdings, and Nan Fung Life Sciences.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com